drugset / Trial / NCT01134237

Intrapleural Urokinase for Retained Hemothorax

NCT01134237

Phase 3 Unknown 32 enrolled National Taiwan University Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Intrapleural thrombolytic treatment with urokinase for retained hemothorax is effective and safe. However, previous study was limited in prospective observation study without control group.

Timeline

Start
2010-05
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Urokinase Protein / enzyme biologic 100000 iu Other

Indications